Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Rectal Neoplasms 1Peritoneal Neoplasms 1Papillomavirus Infections 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Genital Neoplasms, Female 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma in Situ 1Breast Neoplasms 1Appendiceal Neoplasms 1Anus Neoplasms 1

Interventions

pembrolizumab 13Nivolumab 6Gemcitabine 5Paclitaxel 4Cisplatin 4Magnetic Resonance Spectroscopy 3Ipilimumab 3Fluorouracil 3Fluorodeoxyglucose F18 3Carboplatin 3spartalizumab 2fludarabine 2budigalimab 2Oxaliplatin 2Leucovorin 2Irinotecan 2FAPI-46 2Drug Therapy 2Docetaxel 2Cyclophosphamide 2Bevacizumab 2venetoclax 1ulixertinib 1tislelizumab 1seribantumab 1saracatinib 1rovalpituzumab tesirine 1pertuzumab 1pemigatinib 1nilotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cholangiocarcinoma × Electrocardiography × Gynecologic × Clear all
NCT05185947 2026-05-29

Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
21 enrolled 21 charts
BreastGastrointestinalGynecologic

Appendiceal Neoplasms, Breast Neoplasms, Genital Neoplasms, Female, Ovarian Neoplasms, Peritoneal Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡